Mark Higgins
Overview
Explore the profile of Mark Higgins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fidler M, Buckley A, Sullivan J, Statia M, Boj S, Vries R, et al.
Clin Transl Sci
. 2020 Dec;
14(2):656-663.
PMID: 33278322
In previous work, participants with a G970R mutation in cystic fibrosis transmembrane conductance regulator (CFTR) (c.2908G>C) had numerically lower sweat chloride responses during ivacaftor treatment than participants with other CFTR...
12.
Higgins M, Madan C, Patel R
J Surg Educ
. 2020 Dec;
78(4):1328-1339.
PMID: 33257298
Background: In recent years there has been a shift from traditional Halstedian methods toward more simulation-based medical education (SBME) for developing surgical skills. Questions remain about the role and value...
13.
Pilewski J, De Boeck K, Nick J, Tian S, DeSouza C, Higgins M, et al.
Pulm Ther
. 2020 Sep;
6(2):303-313.
PMID: 32965659
Introduction: Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) affect the quantity and/or function of CFTR protein reaching the cell surface. Ivacaftor, a CFTR potentiator that enhances chloride...
14.
Higgins M, Madan C, Patel R
Surgeon
. 2020 Sep;
19(4):e67-e77.
PMID: 32868158
Context: Changes to surgical training programmes in the UK has led to a reduction in theatre time for trainees, and an increasing reliance on simulation to provide procedural experience. Whilst...
15.
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012-2016 Experience
Higgins M, Volkova N, Moy K, Marshall B, Bilton D
Pulm Ther
. 2020 Apr;
6(1):141-149.
PMID: 32304091
Introduction: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and the UK Cystic Fibrosis Registry were used to evaluate the impact of ivacaftor...
16.
Smith F, Lee K, Binnie-McLeod E, Higgins M, Irvine E, Henderson A, et al.
J Infect Prev
. 2020 Feb;
21(1):28-34.
PMID: 32030101
Background: The World Health Organization have designed the fifth of their '5 moments' for hand hygiene to account for microbial transfer from patients to equipment in a narrow area around...
17.
Nick J, St Clair C, Jones M, Lan L, Higgins M
J Cyst Fibros
. 2019 Dec;
19(1):91-98.
PMID: 31784217
Background: Ivacaftor shows benefit in patients with cystic fibrosis (CF) and CFTR mutations associated with residual CF transmembrane conductance regulator (CFTR) function. Here we further assess the effect of ivacaftor...
18.
Higgins M, Jayakumar P, Kortlever J, Rijk L, Galvain T, Drury G, et al.
Knee
. 2019 Nov;
27(2):469-476.
PMID: 31767514
Background: A multi-modal, technology-enabled, patient engagement and pathway management solution (PES) for patients undergoing primary total knee arthroplasty (TKA) was evaluated. The primary outcome measure was length of stay (LoS)....
19.
Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, et al.
J Cyst Fibros
. 2019 Jun;
19(1):68-79.
PMID: 31196670
Background: Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression...
20.
Rosenfeld M, Cunningham S, Harris W, Lapey A, Regelmann W, Sawicki G, et al.
J Cyst Fibros
. 2019 May;
18(6):838-843.
PMID: 31053538
Background: KIWI (NCT01705145) was a 24-week, single-arm, pharmacokinetics, safety, and efficacy study of ivacaftor in children aged 2 to 5 years with cystic fibrosis (CF) and a CFTR gating mutation....